Systems biology of cisplatin resistance: Past, present and future

Cell Death and Disease

Volumn 5, Issue , 2014, Pages

  Galluzzi, L ^a,b,c   Vitale, I ^d,e   Michels, J ^a,c,f   Brenner, C ^f,g   Szabadkai, G ^h,i   Harel Bellan, A ^g,j,k   Castedo, M ^a,c,f   Kroemer, G ^a,b,c,f,l  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f INSERM   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j CNRS   (France)

^k DIF   (France)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

BCL 2; carboplatin; CTR1; DNA damage response; oxaliplatin; p53

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

BIOMICS; CANCER RESISTANCE; DRUG MECHANISM; GENE SILENCING; GENOMICS; GENOTYPE; HUMAN; LARGE SCALE PRODUCTION; METHYLOMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; ANIMAL; DRUG RESISTANCE; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SYSTEMS BIOLOGY;

EID: 84908263722     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.428     Document Type: Review

References (318)

1. Peyrone M. Ueber die Einwirkung des Ammoniaks auf Platinchlorür. Ann Chemie Pharm 1844; 51: 1-29.
2. Burchenal JH, Kalaher K, Dew K, Lokys L. Rationale for development of platinum analogs. Cancer Treat Rep 1979; 63: 1493-1498.
3. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-699.
4. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385-386.
5. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522-1534.
6. Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J Inorg Biochem 1999; 77: 111-115.
7. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584.
8. Prestayko AW, D'Aoust JC, Issell BF, Crooke ST. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 1979; 6: 17-39.
9. Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 2006; 1: 285-295.
10. Winter C, Albers P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2011; 7: 43-53.
11. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008; 299: 672-684.
12. Koberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010; 1806: 172-182.
13. Ozols RF. Ovarian cancer: new clinical approaches. Cancer Treat Rev 1991; 18 (Suppl A): 77-83.
14. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59(Suppl 4): 9-17; discussion 37-18.
15. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39: 1357-1361.
16. Mendoza J, Martinez J, Hernandez C, Perez-Montiel D, Castro C, Fabian-Morales E et al. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br J Cancer 2013; 109: 68-75.
17. Usanova S, Piee-Staffa A, Sied U, Thomale J, Schneider A, Kaina B et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010; 9: 248.
18. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004; 110: 352-361.
19. Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ et al. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One 2012; 7: e51563.
20. Tattersall MN. Ovarian cancer chemotherapy: carboplatin as standard. Lancet 2002; 360: 500-501.
21. Mandala M, Ferretti G, Barni S. Oxaliplatin in colon cancer. N Engl J Med 2004; 351: 1691-1692 (author reply 1691-1692).
22. Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985; 12(Suppl A): 21-33.
23. Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem 1978; 21: 1315-1318.
24. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-1158.
25. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491.
26. Gore ME, Fryatt I, Wiltshaw E, Dawson T, Robinson BA, Calvert AH. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989; 60: 767-769.
27. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993; 53: 5225-5232.
28. Negoro K, Yamano Y, Nakashima D, Saito K, Nakatani K, Shiiba M et al. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line. Oncol Rep 2009; 21: 443-449.
29. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997; 57: 850-856.
30. Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 1995; 71: 676-683.
31. Naredi P, Heath DD, Enns RE, Howell SB. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Cancer Res 1994; 54: 6464-6468.
32. Jones M, Siracky J, Kelland LR, Harrap KR. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer 1993; 67: 24-29.
33. Hill BT, Shellard SA, Hosking LK, Dempke WC, Fichtinger-Schepman AM, Tone T et al. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Cancer Res 1992; 52: 3110-3118.
34. Nishio K, Sugimoto Y, Nakagawa K, Niimi S, Fujiwara Y, Bungo M et al. Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin. Br J Cancer 1990; 62: 415-419.
35. Schwartz JL, Rotmensch J, Beckett MA, Jaffe DR, Toohill M, Giovanazzi SM et al. X-ray and cis-diamminedichloroplatinum(II) cross-resistance in human tumor cell lines. Cancer Res 1988; 48: 5133-5135.
36. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998; 58: 268-275.
37. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 2006; 6: 973-982.
38. Eckardt JR, Bentsion DL, Lipatov ON, Polyakov IS, Mackintosh FR, Karlin DA et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009; 27: 2046-2051.
39. Monneret C. Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr 2011; 69: 286-295.
40. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-5438.
41. el-Khateeb M, Appleton TG, Gahan LR, Charles BG, Berners-Price SJ, Bolton AM. Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques. J Inorg Biochem 1999; 77: 13-21.
42. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000; 59(Suppl 4): 1-8; (discussion 37-38).
43. Eastman A. Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact 1987; 61: 241-248.
44. Michalke B. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. J Trace Elem Med Biol 2010; 24: 69-77.
45. Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev 2006; 106: 2224-2248.
46. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57: 1229-1235.
47. Slater AF, Nobel CS, Maellaro E, Bustamante J, Kimland M, Orrenius S. Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis. Biochem J 1995; 306(Pt 3): 771-778.
48. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-1883.
49. Murata T, Hibasami H, Maekawa S, Tagawa T, Nakashima K. Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int 1990; 20: 949-955.
50. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987; 34: 155-166.
51. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 2006; 12: 5817-5825.
52. Bellon SF, Coleman JH, Lippard SJ. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 1991; 30: 8026-8035.
53. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 1346-1360.
54. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62: 4899-4902.
55. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005; 74: 681-710.
56. Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 2012; 13: 659-671.
57. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75: 685-705.
58. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013; 153: 1194-1217.
59. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12: 385-392.
60. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-120.
61. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13: 780-788.
62. Deniaud A, Sharaf el dein O, Maillier E, Poncet D, Kroemer G, Lemaire C et al. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 2008; 27: 285-299.
63. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-632.
64. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
65. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008; 9: 616-627.
66. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
67. Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 2012; 13: 579-590.
68. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 2013; 73: 3683-3691.
69. Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L et al. Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One 2007; 2: e1337.
70. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
71. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 2009; 10: 481-494.
72. Sancho-Martinez SM, Prieto-Garcia L, Prieto M, Lopez-Novoa JM, Lopez-Hernandez FJ. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 2012; 136: 35-55.
73. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-663.
74. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278: 9100-9106.
75. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007; 120: 175-180.
76. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
77. Yu F, Megyesi J, Price PM. Cytoplasmic initiation of cisplatin cytotoxicity. Am J Physiol Renal Physiol 2008; 295: F44-F52.
78. Gourdier I, Crabbe L, Andreau K, Pau B, Kroemer G. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 2004; 23: 7449-7457.
79. Brenner C, Grimm S. The permeability transition pore complex in cancer cell death. Oncogene 2006; 25: 4744-4756.
80. Godoy LC, Anderson CT, Chowdhury R, Trudel LJ, Wogan GN. Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. Proc Natl Acad Sci USA 2012; 109: 20373-20378.
81. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27: 4221-4232.
82. Sharaf el dein O, Gallerne C, Brenner C, Lemaire C. Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem Pharmacol 2012; 83: 1172-1182.
83. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012; 149: 1536-1548.
84. Vandenbussche F, Vaseva I, Vissenberg K, Van Der Straeten D. Ethylene in vegetative development: a tale with a riddle. New Phytol 2012; 194: 895-909.
85. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-590.
86. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014.
87. Hodeify R, Megyesi J, Tarcsafalvi A, Safirstein RL, Price PM. Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase. Am J Physiol Renal Physiol 2010; 299: F112-F120.
88. Yoshida M, Khokhar AR, Siddik ZH. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Cancer Res 1994; 54: 3468-3473.
89. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298-14302.
90. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002; 62: 6559-6565.
91. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006; 70: 1390-1394.
92. More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR, Giacomini KM. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 2010; 30: 9500-9509.
93. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010; 17: 574-583.
94. Zischka H, Lichtmannegger J, Schmitt S, Jagemann N, Schulz S, Wartini D et al. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J Clin Invest 2011; 121: 1508-1518.
95. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000; 60: 1312-1316.
96. Safaei R, Holzer AK, Katano K, Samimi G, Howell SB. The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 2004; 98: 1607-1613.
97. Aida T, Takebayashi Y, Shimizu T, Okamura C, Higasimoto M, Kanzaki A et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol 2005; 97: 41-45.
98. Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 2002; 101: 488-495.
99. Nakayama K, Kanzaki A, Terada K, Mutoh M, Ogawa K, Sugiyama T et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 2004; 10: 2804-2811.
100. Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 2008; 8: 175.
101. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW et al. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 2012; 75: 228-234.
102. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 2012; 72: 4616-4621.
103. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther 2012; 11: 1221-1225.
104. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M et al. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther 2012; 11: 2483-2494.
105. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-937.
106. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57: 5475-5479.
107. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003; 121: 172-176.
108. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Takamura M et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 2010; 23: 965-972.
109. Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 2011; 104: 707-713.
110. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R et al. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 2013; 123: 2119-2130.
111. Lewis AD, Hayes JD, Wolf CR. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 1988; 9: 1283-1287.
112. Chen HH, Kuo MT. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010; 2010: Article ID: 430939.
113. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-1815.
114. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991; 51: 3237-3242.
115. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84: 1512-1517.
116. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316.
117. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304.
118. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
119. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 3855-3859.
120. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18: 522-528.
121. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008; 14: 4225-4231.
122. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008; 99: 167-172.
123. Olaussen KA. A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin. Cancer Biol Ther 2009; 8: 1922-1923.
124. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368: 1101-1110.
125. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58: 3579-3585.
126. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-3090.
127. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996; 271: 19645-19648.
128. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
129. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52.
130. Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010; 16: 1206-1215.
131. Bassett E, Vaisman A, Tropea KA, McCall CM, Masutani C, Hanaoka F et al. Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta. DNA Repair (Amst) 2002; 1: 1003-1016.
132. Zhao Y, Biertumpfel C, Gregory MT, Hua YJ, Hanaoka F, Yang W. Structural basis of human DNA polymerase eta-mediated chemoresistance to cisplatin. Proc Natl Acad Sci USA 2012; 109: 7269-7274.
133. Wittschieben JP, Reshmi SC, Gollin SM, Wood RD. Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells. Cancer Res 2006; 66: 134-142.
134. Roos WP, Tsaalbi-Shtylik A, Tsaryk R, Guvercin F, de Wind N, Kaina B. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. Mol Pharmacol 2009; 76: 927-934.
135. Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng L et al. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. Neuro Oncol 2009; 11: 790-802.
136. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108: 73-112.
137. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
138. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-182.
139. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
140. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
141. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13: 1383-1388.
142. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120.
143. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115.
144. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13: 411-424.
145. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73: 2271-2280.
146. Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 2013; 12: 877-883.
147. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737.
148. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.
149. Karasawa T, Sibrian-Vazquez M, Strongin RM, Steyger PS. Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds. PLoS One 2013; 8: e66220.
150. Yao Z, Jones AW, Fassone E, Sweeney MG, Lebiedzinska M, Suski JM et al. PGC-1beta mediates adaptive chemoresistance associated with mitochondrial DNA mutations. Oncogene 2013; 32: 2592-2600.
151. Mizutani S, Miyato Y, Shidara Y, Asoh S, Tokunaga A, Tajiri T et al. Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs. Cancer Sci 2009; 100: 1680-1687.
152. Jones AW, Yao Z, Vicencio JM, Karkucinska-Wieckowska A, Szabadkai G. PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. Mitochondrion 2012; 12: 86-99.
153. Abu-Hamad S, Sivan S, Shoshan-Barmatz V. The expression level of the voltage-dependent anion channel controls life and death of the cell. Proc Natl Acad Sci USA 2006; 103: 5787-5792.
154. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
155. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
156. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
157. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228.
158. Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaa M, Castedo M et al. Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ 2011; 18: 1403-1413.
159. Chao CC, Huang SL, Huang HM, Lin-Chao S. Cross-resistance to UV radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified DNA. Mol Cell Biol 1991; 11: 2075-2080.
160. Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer PH, Debatin KM et al. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer 2004; 108: 580-587.
161. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40: 280-293.
162. Vicencio JM, Galluzzi L, Tajeddine N, Ortiz C, Criollo A, Tasdemir E et al. Senescence, apoptosis or autophagy? When a damaged cell must decide its path - a mini-review. Gerontology 2008; 54: 92-99.
163. Mandic A, Viktorsson K, Varsanyi M, Hansson J, Linder S, Shoshan M. BAK, BAX and p53 proteins in the apoptotic response to cisplatin. Nat Genet 2001; 27: 86.
164. Kim JS, Lee JH, Jeong WW, Choi DH, Cha HJ, Kim do H et al. Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer 2008; 122: 672-680.
165. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res 2012; 111: 1198-1207.
166. Branch P, Masson M, Aquilina G, Bignami M, Karran P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000; 19: 3138-3145.
167. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-4300.
168. Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemuller J, Schiffer I et al. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer 2001; 95: 121-127.
169. Gadducci A, Cosio S, Muraca S, Genazzani AR. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol 2002; 23: 390-396.
170. Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV et al. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci USA 2012; 109: E68-E75.
171. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004; 112: 974-985.
172. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 278: 19245-19256.
173. Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 2001; 14: 305-315.
174. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67: 6253-6262.
175. Han JY, Hong EK, Choi BG, Park JN, Kim KW, Kang JH et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol 2003; 20: 355-362.
176. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1645-1654.
177. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96: 287-295.
178. Erovic BM, Pelzmann M, Grasl M, Pammer J, Kornek G, Brannath W et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res 2005; 11: 8632-8636.
179. Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 2004; 95: 44-51.
180. Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Pilecka I, Jablonka A. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 2005; 43: 237-242.
181. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95: 92-95.
182. Ikeguchi M, Kaibara N. Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int J Mol Med 2001; 8: 661-666.
183. Keating J, Tsoli M, Hallahan AR, Ingram WJ, Haber M, Ziegler DS. Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in medulloblastoma. Mol Cancer Ther 2012; 11: 2654-2663.
184. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
185. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18: 3163-3169.
186. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27: 4481-4486.
187. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26: 5198-5203.
188. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68: 505-511.
189. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
190. Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M et al. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 1999; 59: 3206-3214.
191. Fijolek J, Wiatr E, Rowinska-Zakrzewska E, Giedronowicz D, Langfort R, Chabowski M et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers 2006; 21: 81-87.
192. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3: 245-252.
193. Deng X, Ewton DZ, Friedman E. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species. Cancer Res 2009; 69: 3317-3324.
194. Shen DW, Gottesman MM. RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res 2012; 29: 643-650.
195. Shen DW, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM. Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol 2010; 225: 822-828.
196. Messina S, Leonetti C, De Gregorio G, Affatigato V, Ragona G, Frati L et al. Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. Biochem Biophys Res Commun 2004; 320: 493-500.
197. Yu H, Su J, Xu Y, Kang J, Li H, Zhang L et al. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer 2011; 47: 1585-1594.
198. Ren JH, He WS, Nong L, Zhu QY, Hu K, Zhang RG et al. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 2010; 25: 75-80.
199. Zhang Y, Shen X. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 2007; 13: 2855-2864.
200. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 2001; 168: 173-181.
201. Ren A, Yan G, You B, Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res 2008; 68: 2266-2274.
202. Miyazaki T, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y et al. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res 2005; 25: 2749-2755.
203. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012; 64: 706-721.
204. He JC, Chuang PY, Ma'ayan A, Iyengar R. Systems biology of kidney diseases. Kidney Int 2012; 81: 22-39.
205. Lee NH, Saeed AI. Microarrays: an overview. Methods Mol Biol 2007; 353: 265-300.
206. Nilsson T, Mann M, Aebersold R, Yates JR 3rd, Bairoch A, Bergeron JJ. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 2010; 7: 681-685.
207. Monetti M, Nagaraj N, Sharma K, Mann M. Large-scale phosphosite quantification in tissues by a spike-in SILAC method. Nat Methods 2011; 8: 655-658.
208. Johnson SA, Hunter T. Kinomics: methods for deciphering the kinome. Nat Methods 2005; 2: 17-25.
209. Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, Mani DR et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 2013; 10: 634-637.
210. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
211. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
212. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-196.
213. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-190.
214. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
215. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108-112.
216. Cui L, Fu J, Pang JC, Qiu ZK, Liu XM, Chen FR et al. Overexpression of IL-7 enhances cisplatin resistance in glioma. Cancer Biol Ther 2012; 13: 496-503.
217. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996; 88: 1731-1737.
218. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D et al. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene 2011; 30: 3163-3173.
219. Yu W, Jin C, Lou X, Han X, Li L, He Y et al. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One 2011; 6: e29450.
220. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012; 31: 4567-4576.
221. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V et al. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 2013; 62: 22-33.
222. Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB et al. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol 2012; 124: 119-124.
223. Yu HM, Wang TC. Mechanism of cisplatin resistance in human urothelial carcinoma cells. Food Chem Toxicol 2012; 50: 1226-1237.
224. Lai TC, Chow KC, Fang HY, Cho HC, Chen CY, Lin TY et al. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients. Oncol Rep 2011; 25: 1243-1251.
225. Koch M, Krieger ML, Stolting D, Brenner N, Beier M, Jaehde U et al. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling. Biochem Pharmacol 2013; 85: 1077-1090.
226. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 2011; 17: 6356-6366.
227. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One 2011; 6: e16694.
228. Barlin JN, Jelinic P, Olvera N, Bogomolniy F, Bisogna M, Dao F et al. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol Oncol 2013; 128: 512-517.
229. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 2013; 49: 520-530.
230. Tomkiewicz C, Hans S, Mucchielli MH, Agier N, Delacroix H, Marisa L et al. A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanes. PLoS One 2012; 7: e47170.
231. Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle 2012; 11: 3472-3480.
232. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70: 1793-1803.
233. Guo Y, Yan K, Fang J, Qu Q, Zhou M, Chen F. Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res 2013; 32: 41.
234. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012; 31: 432-445.
235. Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X et al. miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res 2013; 19: 677-683.
236. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012; 29: 384-391.
237. Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011; 37: 427-434.
238. Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cells. PLoS One 2013; 8: e65309.
239. Zhuo L, Liu J, Wang B, Gao M, Huang A. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013; 29: 555-562.
240. Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 2012; 28: 592-600.
241. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012; 586: 1279-1286.
242. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011; 4: 79.
243. Ko MA, Zehong G, Virtanen C, Guindi M, Waddell TK, Keshavjee S et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg 2012; 94: 1094-1102.
244. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-1281.
245. Zhu J, Jiang Z, Gao F, Hu X, Zhou L, Chen J et al. A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer. PLoS One 2011; 6: e28223.
246. Bangert A, Hacker S, Cristofanon S, Debatin KM, Fulda S. Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anticancer Drugs 2011; 22: 494-499.
247. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007; 30: 1181-1188.
248. Wang F, Liu M, Li X, Tang H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett 2013; 587: 488-495.
249. Eriksson I, Joosten M, Roberg K, Ollinger K. The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis. Exp Cell Res 2013; 319: 12-20.
250. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 2008; 99: 376-384.
251. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 2009; 100: 758-763.
252. Qiu YY, Mirkin BL, Dwivedi RS. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev 2005; 29: 456-463.
253. Chavez JD, Hoopmann MR, Weisbrod CR, Takara K, Bruce JE. Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells. PLoS One 2011; 6: e19892.
254. Zeng HZ, Qu YQ, Zhang WJ, Xiu B, Deng AM, Liang AB. Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer. Int J Mol Sci 2011; 12: 3489-3499.
255. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013; 23: 811-825.
256. Aichler M, Elsner M, Ludyga N, Feuchtinger A, Zangen V, Maier SK et al. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol 2013; 230: 410-419.
257. Vasko R, Mueller GA, von Jaschke AK, Asif AR, Dihazi H. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis. Eur J Pharmacol 2011; 670: 50-57.
258. Chappell NP, Teng PN, Hood BL, Wang G, Darcy KM, Hamilton CA et al. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J Proteome Res 2012; 11: 4605-4614.
259. Zhang G, Sun L, Lu X, Chen Z, Duerksen-Hughes PJ, Hu H et al. Cisplatin treatment leads to changes in nuclear protein and microRNA expression. Mutat Res 2012; 746: 66-77.
260. Shetty V, Nickens Z, Testa J, Hafner J, Sinnathamby G, Philip R. Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells. J Proteomics 2012; 75: 3270-3290.
261. Garand C, Guay D, Sereduk C, Chow D, Tsofack SP, Langlois M et al. An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells. Cancer Sci 2011; 102: 1410-1417.
262. Huang W, Ding X, Li B, Fan M, Zhou T, Sun H et al. Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy. Neoplasma 2013; 60: 11-18.
263. Han M, Dai J, Zhang Y, Lin Q, Jiang M, Xu X et al. Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer. Oncol Rep 2012; 28: 2233-2238.
264. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39: 74-88.
265. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215-233.
266. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 2004; 432: 1036-1040.
267. Sachse C, Echeverri CJ. Oncology studies using siRNA libraries: the dawn of RNAi-based genomics. Oncogene 2004; 23: 8384-8391.
268. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25-35.
269. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 2000; 60: 2964-2972.
270. Alcala S, Klee M, Fernandez J, Fleischer A, Pimentel-Muinos FX. A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. Oncogene 2008; 27: 44-54.
271. Sun C, Newbatt Y, Douglas L, Workman P, Aherne W, Linardopoulos S. High-throughput screening assay for identification of small molecule inhibitors of Aurora2/STK15 kinase. J Biomol Screen 2004; 9: 391-397.
272. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2: 257-269.
273. Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P et al. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle 2013; 12: 417-421.
274. Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer 2012; 11: 26.
275. Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J et al. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol 2011; 18: 1390-1400.
276. Salm F, Cwiek P, Ghosal A, Lucia Buccarello A, Largey F, Wotzkow C et al. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. Oncogene 2013; 32: 3944-3953.
277. Ho H, Aruri J, Kapadia R, Mehr H, White MA, Ganesan AK. RhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damage. Cancer Res 2012; 72: 5516-5528.
278. Li G, Alexander H, Schneider N, Alexander S. Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium. Microbiology 2000; 146(Pt 9): 2219-2227.
279. Liao C, Hu B, Arno MJ, Panaretou B. Genomic screening in vivo reveals the role played by vacuolar H+ ATPase and cytosolic acidification in sensitivity to DNA-damaging agents such as cisplatin. Mol Pharmacol 2007; 71: 416-425.
280. Gatti L, Hoe KL, Hayles J, Righetti SC, Carenini N, Bo LD et al. Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast. BMC Genomics 2011; 12: 44.
281. Sletta H, Klinkenberg G, Winnberg A, Kvitvang HF, Nilsen MB, Krokan HE et al. A new high resolution screening method for study of phenotype stress responses of Saccharomyces cerevisae mutants. J Microbiol Methods 2011; 87: 363-367.
282. Galluzzi L, Vacchelli E, Michels J, Garcia P, Kepp O, Senovilla L et al. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene 2013; 32: 4995-5004.
283. Galluzzi L, Goubar A, Olaussen KA, Vitale I, Senovilla L, Michels J et al. Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle 2013; 12: 647-654.
284. Guerreiro AS, Fattet S, Kulesza DW, Atamer A, Elsing AN, Shalaby T et al. A sensitized RNA interference screen identifies a novel role for the PI3K p110gamma isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res 2011; 9: 925-935.
285. Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM et al. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012; 72: 5945-5955.
286. Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 2011; 128: 301-313.
287. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-575.
288. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359: 1033-1034.
289. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359: 397-401.
290. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR et al. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 2012; 18: 3705-3713.
291. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R. Orotate phosphoribosyl-transferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12: 3928-3934.
292. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306: 640-643.
293. Han B, Gao G, Wu W, Gao Z, Zhao X, Li L et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 2011; 72: 238-243.
294. Cheng J, Ha M, Wang Y, Sun J, Chen J, Wang Y et al. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2012; 138: 231-238.
295. Yu D, Shi J, Sun T, Du X, Liu L, Zhang X et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol 2012; 33: 877-884.
296. Qian J, Gu S, Wu Q, Zhao X, Wu W, Gao Z et al. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. Chest 2012; 142: 680-689.
297. Qian J, Qu HQ, Yang L, Yin M, Wang Q, Gu S et al. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Oncologist 2012; 17: 1551-1561.
298. Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T et al. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 2005; 11: 1237-1246.
299. Lin CH, Yeakley JM, McDaniel TK, Shen R. Medium- to high-throughput SNP genotyping using VeraCode microbeads. Methods Mol Biol 2009; 496: 129-142.
300. Paynter RA, Skibola DR, Skibola CF, Buffler PA, Wiemels JL, Smith MT. Accuracy of multiplexed Illumina platform-based single-nucleotide polymorphism genotyping compared between genomic and whole genome amplified DNA collected from multiple sources. Cancer Epidemiol Biomarkers Prev 2006; 15: 2533-2536.
301. Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012; 1: 271-278.
302. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011; 17: 5801-5811.
303. Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ et al. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One 2011; 6: e21920.
304. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2013; 13: 35-43.
305. Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, Croghan GA et al. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res 2011; 17: 3830-3840.
306. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011; 103: 817-825.
307. Hu L, Wu C, Zhao X, Heist R, Su L, Zhao Y et al. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2012; 18: 5507-5514.
308. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-1552.
309. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15: 19-27.
310. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30: 2509-2515.
311. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147-156.
312. Andjilani M, Droz JP, Benahmed M, Tabone E. Alpha6 integrin subunit mediates laminin enhancement of cisplatin-induced apoptosis in testicular tumor germ cells. Int J Cancer 2005; 117: 68-81.
313. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011; 20: 370-383.
314. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013; 24: 311-318.
315. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
316. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012; 21: 488-503.
317. Sasada S, Miyata Y, Tsutani Y, Tsuyama N, Masujima T, Hihara J et al. Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil. Oncol Rep 2013; 29: 925-931.
318. Wang X, Yan SK, Dai WX, Liu XR, Zhang WD, Wang JJ. A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer. Int J Cancer 2010; 127: 2841-2850.